Home > Nanotechnology Columns > Bergeson & Campbell, P.C. > EUON Publishes Nanopinion on Urinary MicroRNA-based Early Cancer Detection Using Nanowire-based Devices
Lynn L. Bergeson Managing Director Bergeson & Campbell, P.C. |
Abstract:
On May 31, 2022, the European Union (EU) Observatory for Nanomaterials (EUON) published a Nanopinion entitled "Urinary MicroRNA-based Early Cancer Detection Using Nanowire-based Devices" by Dr. Takao Yasui on using nanowire devices to extract microRNAs (miRNA) from urine to distinguish cancer patients from healthy individuals and improve the early detection of cancer.
June 9th, 2022
EUON Publishes Nanopinion on Urinary MicroRNA-based Early Cancer Detection Using Nanowire-based Devices
On May 31, 2022, the European Union (EU) Observatory for Nanomaterials (EUON) published a Nanopinion entitled "Urinary MicroRNA-based Early Cancer Detection Using Nanowire-based Devices" by Dr. Takao Yasui on using nanowire devices to extract microRNAs (miRNA) from urine to distinguish cancer patients from healthy individuals and improve the early detection of cancer. See https://euon.echa.europa.eu/nanopinion/-/blogs/urinary-microrna-based-early-cancer-detection-using-nanowire-based-devices According to Yasui, researchers designed a device equipped with 100 million zinc oxide nanowires that can extract a significantly greater variety and quantity of miRNAs from only a milliliter of urine compared to conventional methods. Using the device, they revealed that miRNAs in urine could be a promising biomarker to diagnose brain tumors, finding that many miRNAs derived from brain tumors exist in urine in a stable condition. Yasui states that the results showed that the model can distinguish the patients from non-cancer individuals at a sensitivity of 100 percent and a specificity of 97 percent, regardless of the malignancy and size of tumors.
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||